* Absci Corp ABSI.OQ reported a quarterly adjusted loss
of 22
cents per share for the quarter ended in March, higher than
the same quarter last year, when the company reported EPS of -26
cents. The mean expectation of six analysts for the quarter was
for a loss of 21 cents per share. Wall Street expected
results to range from -27 cents to -14 cents per share.
* Revenue fell 29.2% to $898.00 thousand from a year ago;
analysts
expected $2.42 million.
* Absci Corp's reported EPS for the quarter was a loss of 22
cents.
* The company reported a quarterly loss of $21.98 million.
* Absci Corp shares had fallen by 10.9% this quarter and
gained 20.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 17.8%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Absci Corp is
$8.00
This summary was machine generated from LSEG data May 14 at
02:09 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.21 -0.22 Missed
Dec. 31 2023 -0.25 -0.25 Met
Sep. 30 2023 -0.23 -0.24 Missed
Jun. 30 2023 -0.24 -0.45 Missed